Indraprastha Apollo Hospitals, New Delhi, India.
Formerly with CSIR-NISTADS, New Delhi, 110012, India.
Diabetes Metab Syndr. 2023 Nov;17(11):102898. doi: 10.1016/j.dsx.2023.102898. Epub 2023 Nov 7.
BACKGROUND AND AIMS: This study aimed to assess the current status of India's COVID-19 research from the top 100 most cited papers, using bibliometrics methods and indicators and suggest strengths and weaknesses. METHODOLOGY: Publications on COVID-19 research from India between December 2019 and 22 August 2023 were retrieved from the Scopus database. From 37101 studies retrieved, the first top 100 Highly Cited Papers (HCPs) having received 270 to 2931 citations, were identified. RESULTS: The top 100 most cited Indian papers were published from 2020 to 2023, with the majority (75) in the year 2021, followed by 24 in 2022. They were cited a total of 56661 times (average - 566.61 times). The 242 authors of these HCPs were from 159 Indian organizations, and the articles were published in 60 journals. 29 % and 59 % of these HCPs received external funding support and were involved in international collaborations, respectively. There was poor collaboration among Indian research institutions and a dearth of funding from India. None of the Indian HCPs figured in the global 100 HCPs. CONCLUSIONS: Although citations of research papers published from India increased during COVID-19, limited collaboration, inadequate funding, and subpar publications hindered Indian scientists. To enhance India's research landscape, we propose dismantling barriers, nurturing collaboration, and encouraging knowledge exchange among domestic institutions.
背景和目的:本研究旨在使用文献计量学方法和指标评估印度 COVID-19 研究的现状,从被引频次最高的前 100 篇论文中找出优势和劣势。
方法:从 Scopus 数据库中检索 2019 年 12 月至 2023 年 8 月 22 日期间发表的有关印度 COVID-19 研究的出版物。从检索到的 37101 项研究中,确定了前 100 篇被引频次最高的论文(HCP),这些论文的被引频次在 270 到 2931 次之间。
结果:前 100 篇被引频次最高的印度论文发表于 2020 年至 2023 年,其中 2021 年发表的最多(75 篇),其次是 2022 年(24 篇)。这些论文共被引用 56661 次(平均每篇 566.61 次)。这些 HCP 的 242 位作者来自印度的 159 个组织,文章发表在 60 种期刊上。29%和 59%的 HCP 获得了外部资金支持,分别参与了国际合作。印度研究机构之间的合作不佳,印度的资金也不足。没有一篇印度的 HCP 进入全球 100 篇 HCP 之列。
结论:尽管印度发表的研究论文的引用量在 COVID-19 期间有所增加,但有限的合作、不足的资金和较差的出版物阻碍了印度科学家的发展。为了加强印度的研究格局,我们建议打破障碍,培育合作,鼓励国内机构之间的知识交流。
Diabetes Metab Syndr. 2023-11
Asian J Psychiatr. 2021-2
Diabetes Metab Syndr. 2020
Health Res Policy Syst. 2018-3-1
Diabetes Metab Syndr. 2021
Asian J Psychiatr. 2021-1
J Nepal Health Res Counc. 2024-6-21
Diabetes Metab Syndr. 2021
Indian J Orthop. 2024-4-27
Indian J Orthop. 2024-5-2
J Clin Orthop Trauma. 2024-2-24